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Abstract 
A significant portion of patients with chronic hepatitis B virus (HBV) infection are in the inactive 
carrier state, characterized by normal transaminase levels, little viral replication and minimal liver 
necroinflammatory activity. Diagnosis is made after at least one year of regular monitoring and 
requires lifelong follow-up to confirm that this state is maintained. 
Studying the natural history of inactive carriers is currently hindered by the small number of studies 
with cohorts correctly diagnosed according to the latest guidelines. 
When correctly defined, inactive carrier state carries a very good prognosis in the spectrum of 
chronic hepatitis B infection, with low rates of reactivation, hepatocellular carcinoma and 
progression of disease to cirrhosis. In addition, clearance of hepatitis B surface antigen is more 
common in inactive carriers compared to the general HBV infected population. Reactivation is more 
likely during the first years of follow-up and during immunosuppressive therapies: prophylactic 
antiviral treatment should be initiated as soon as possible in this latter case. 
Current guidelines do not routinely recommend liver biopsy in inactive carriers. However, some may 
have significant hepatic fibrosis at diagnosis and cannot therefore be classified as such; others may 
develop fibrosis during follow-up and consequentially have poorer prognosis.  Transient elastography 
appears an ideal approach for identifying such patients and for serial monitoring of liver disease in all 
inactive carriers. 
Overall, more longitudinal studies on larger cohorts of true inactive carriers would be helpful for 
better understanding this chronic hepatitis B subpopulation. 
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Introduction 
Infection with hepatitis B virus (HBV) affects approximately one third of the world’s population during 
their lifetime [1]. It is estimated that 240 million people worldwide have chronic HBV infection. It is 
especially prevalent in Sub-Saharan Africa and East Asia, where perinatal transmission accounts for 
the majority of cases. Transmission can occur through body fluids such as blood, semen or vaginal 
secretions; the major routes of infection are perinatal, sexual and blood-to-blood contact [2]. 
Following acute exposure to HBV, the natural history of HBV infection goes sequentially through the 
following two phases: 
A) the immune-tolerant phase is characterized by hepatitis B early antigen (HBeAg) positivity (a 
serological marker of viral replication), high viral replication rate (elevated HBV DNA levels) and 
normal alanine aminotransferase (ALT) levels. There is little to no inflammation or fibrosis of the liver. 
This phase tends to be more prolonged in perinatally acquired infection. 
B) in the immune-reactive phase the host’s immune system starts mounting a response against HBV: 
replication levels lower, with a parallel drop in serum HBV DNA, ALT levels rise and there is moderate 
to severe necroinflammatory activity in the liver with resultant hepatocyte lysis. This phase ends with 
HBeAg loss and seroconversion to anti-HBe status, which is usually associated with viral suppression 
by the host’s immune system [1]. The likelihood of clearing the virus during this phase, evidenced 
serologically by hepatitis B surface antigen (HBsAg) loss, depends largely on patient’s age at the time 
of infection, so that chronicity occurs in 80-90% of infected newborns, in contrast with 30-50% if 
infection is acquired in early childhood and only <5% if infected in adulthood [2]. 
Chronic HBV infection is defined by persistent HBsAg positivity for >6 months and clinical 
manifestations are varied and possibly dynamic: 
C) Some patients remain in an inactive carrier (IC) state, defined by the European Association for the 
Study of the Liver (EASL) as fulfilling the following criteria: 1) HBeAg negativity; 2) anti-Hbe positivity; 
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3) persistently normal ALT (PNALT) levels (<40 IU/mL, with measurements at least every 3 to 4 
months during 1 year); 4) serum HBV DNA levels <2000 IU/mL. 
D) Others evolve to HBeAg-negative chronic hepatitis B (CHB), usually associated with precore or 
basal core promoter mutant HBV. It is characterized by fluctuating ALT and serum HBV DNA levels 
that may even drop below IC cut-off levels, despite persistent viral replication and hepatic 
inflammation. 
Differentiating between inactive carrier and CHB status is of paramount importance in clinical 
practice, since it has serious implications in follow-up, management and prognosis [1]. 
Definition of inactive chronic HBV carriers 
HBA DNA and ALT cut-off levels 
At the Management of Hepatitis B workshop in 2000, an arbitrary level of 20.000 IU/mL was adopted 
as the serum HBV DNA cut-off level distinguishing active and inactive chronic hepatitis [3]. Afterwards 
it was demonstrated that this cut-off would misclassify 45% and 30% of active CHB based on one or 
three serial HBV DNA measurements, respectively [4], which led major guidelines to adopt a lower 
serum HBV DNA cut-off value of 2000 IU/mL [1, 5]. Still, the EASL acknowledges that there may be 
some inactive carriers with viremia levels between 2000 and 20.000 IU/mL.  
Debate on the value that best discriminates between active and inactive infection is ongoing. Chen et 
al. followed 64 inactive carriers who maintained PNALT during a mean follow-up period of 17,6 years 
and measured HBV DNA levels periodically (minimum of 5 measurements); 68% had at least one HBV 
DNA level >2000 IU/mL (excluding those obtained during the first year of follow-up) [6]. 
Because HBV DNA levels in HBe-negative active hepatitis can fluctuate from undetectable to 
>2.000.000 IU/mL [5] and some inactive carriers occasionally have HBV DNA levels between 2000 and 
20.000 IU/mL, a single HBV DNA level between 2000 and 20.000 IU/mL appears to be in a “grey area” 
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which can correspond to both active CHB or inactive carriers. It is thus important for the clinician to 
be aware of the importance of serial HBV DNA measurements and life-long follow-up to confirm the 
diagnosis and that inactive carrier state is maintained. 
Another inactive carrier state diagnostic criterion has recently been revised: lower ALT upper limit of 
normal (ULN) levels of 30 IU/L for men and 19 IU/L for women were proposed based on its 95th 
percentile in healthy Italian blood donor candidates [5]. Indeed, there appear to exist differences in 
viremia, risk of reactivation and liver histological lesions between patients with low-normal 
(<0,5xULN) and high-normal ALT (0,5-1xULN), as a review by Andreani recently summarized [7]. 
However, most of these results come from studies on chronic HBV populations with heterogeneous 
serological profiles and HBV DNA levels. These observations may therefore not  extend to inactive 
carriers, especially since several prospective studies on HBe-negative carriers with PNALT failed to 
demonstrate significant differences in clinical outcomes between patients with higher-normal and 
lower-normal ALT levels [8, 9]. It remains to be determined whether ALT levels near the ULN warrant 
management changes for inactive carriers. 
HBsAg quantification 
The HBV marker HBsAg has been the foundation of HBV infection diagnosis since its discovery over 
40 years ago; however, its significance in clinical practice has mostly been limited to qualitative 
status. Recently, interest has sparked regarding its quantification as an important diagnostic, 
prognostic and predictive tool [10]. 
HBsAg is the glycosylated protein of the HBV virion envelope. The DNA template for HBV replication 
exists in hepatocytes’ nuclei as covalently closed circular DNA (cccDNA) and segments of it can 
become integrated in the host’s hepatocyte genome. Unlike mature virions, HBsAg can also be 
sinthetised from integrated HBV DNA. It is produced in excess of mature virions and consequently 
exists in circulation both associated with virions and as subviral particles. 
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HBsAg levels tend to decline as disease progresses to HBe-negativity and inactivity but they re-
elevate if there is reactivation to active hepatitis [11]. Several cross-sectional [12-14] and longitudinal 
[15-17] studies have also demonstrated a significant difference in HBsAg levels between inactive 
carriers versus active HBe-negative chronic hepatitis, revealing its potential usefulness in 
discriminating between the two. Using a HBsAg cut-off level of 650 IU/mL, Brunetto et al. found a 
diagnostic accuracy of 88% for diagnosing inactive carriers in a population of 209 Italian treatment-
naïve HBe-negative genotype D infected patients; sensitivity, specificity, positive predictive value 
(PPV) and negative predictive value (NPV) were 82%, 90%, 75% and 93%, respectively [16]. 
In addition, HBsAg appears to have prognostic significance for both HBsAg seroclearance and disease 
reactivation. Lower baseline HBsAg levels and yearly HBsAg decline are independently associated 
with subsequent HBsAg loss [16]. In a Taiwanese study on HBe-negative treatment-naïve patients, 
baseline HBsAg <50 IU/mL could predict HBsAg loss during a median follow-up of 8 years with 82% 
sensitivity and 67% specificity [18]. In another study on  Korean genotype C-infected inactive carriers, 
baseline HBsAg >850 IU/mL and HBV DNA >850 IU/mL could predict reactivation with 85% accuracy, 
65% sensitivity, 93% specificity, 80% PPV and 86% NPV [15]. 
Interestingly, while HBsAg correlates strongly with serum HBV DNA in global chronic hepatitis B 
populations [13, 19], correlation is only weak in HBe-negative patients [12, 15, 20, 21]. It appears that 
HBsAg levels don’t fall in the same proportion as HBV DNA levels as disease progresses. Accordingly, 
the serum HBV DNA/HBsAg ratio seems to be significantly higher in active CHB versus inactive HBV 
carriers [12, 14, 19, 20]. 
Indeed, it is the combination of serum HBsAg and HBV DNA levels that shows most promise as a 
single-point measurement for differentiating active CHB versus inactive carriers. A single-point 
measurement of serum HBsAg (cut-off <1000 IU/mL) and HBV DNA (cut-off ≤2000 IU/mL) in the 
above mentioned Italian study achieved an even better discriminatory power between these two 
stages of chronic HBV infection (94% diagnostic accuracy, 91% sensitivity, 95% specificity, 88% PPV, 
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97% NPV) [16]. However, Park et al. tested these cut-offs in 104 Korean treatment-naïve genotype C 
HBe-negative patients and obtained poorer values: 62% diagnostic accuracy, 55% sensitivity, 77% 
specificity, 85% PPV and 42 % NPV [15], demonstrating the need for further studies in larger cohorts 
of HBV infected patients with different characteristics to confirm these data. 
Liver histology 
Inactive carriers have by definition minimal to no necroinflammatory activity in the liver. However, 
because liver biopsy is seldom recommended in these patients, this is rarely confirmed histologically. 
Serial liver biopsies are evidently even less frequently performed, making follow-up of liver histologic 
changes in inactive carrier populations difficult to evaluate using this method [1]. 
A recent review raised the concern that in approximately 10% of inactive HBV carriers diagnosed 
using ALT and HBV DNA levels significant liver disease might be missed [22], based on liver biopsies 
conducted on Indian and French inactive carriers. 
Indeed, a 2012 systematic review of 6 studies with liver histology data from inactive carriers (which 
included the two above-mentioned studies) concluded that mild liver necroinflammatory activity and 
moderate fibrosis were present in 10% and 8% of patients, respectively, when inactive carrier state 
diagnosis was appropriate. In contrast, studies with poor definitions of PNALT, viremia levels >2000 
IU/mL and/or significant baseline liver disease found a higher proportion of moderate to severe liver 
changes [23]. 
Liver biopsy is the gold-standard for evaluation of disease activity and liver fibrosis in HBV infection; it 
is however invasive, observer-dependent and carries a small risk of serious complications [1], which 
makes its use in asymptomatic patients with modest clinical disease open to question. 
Transient elastography is a recent simple and non-invasive alternative method for fibrosis assessment 
based on liver stiffness measured with an ultrasonographic method. It has been shown to be accurate 
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and reproducible in hepatitis B [24] and might supplant liver biopsy in assessing fibrosis in these 
patients. 
Liver stiffness is significantly lower in inactive carriers (defined using previous cut-off of 20.000 
IU/mL) than in HBe-negative active hepatitis patients and was similar to that of healthy controls in 
three European studies [25-27]. In inactive carriers and untreated HBe-negative CHB patients, its 
diagnostic accuracy for the presence of Ishak fibrosis score ≥3 was 90,1% (sensitivity, 93,9%; 
specificity, 88,5%; PPV, 76,7%; NPV, 97,3%) and 94,2% for diagnosing cirrhosis (sensitivity, 86.5%; 
specificity, 96.3%; PPV, 86.5%; NPV, 96.3%) [25]. The cut-offs used were those with greater areas 
under ROC curve (AUROCs): 7,5 pKa and 11,8 pKa for diagnosing Ishak fibrosis score ≥3 and cirrhosis, 
respectively. These results are similar to those proposed in a 2012 systematic review of 
heterogeneous chronic hepatitis B patients (7,9 and 11,7 pKa for METAVIR fibrosis score ≥2 and 
cirrhosis, respectively). The same review points out that transient elastography in HBV infection may 
yield false results under certain circumstances. On the one hand, liver stiffness readings increase with 
active hepatic inflammation and falsely elevated results are possible if there is substantial ALT 
elevation. On the other hand, falsely low values may result from the ultrasound beam missing fibrotic 
bands, especially considering the macronodular nature of cirrhosis in HBV infection [24].  
However, there is another important aspect other than the staging of fibrosis that could reinforce the 
need for performing liver biopsies in these patients: the determination of the amount of HBV 
infected hepatocytes, which currently relies on a liver tissue sample. Nonetheless, HBsAg 
quantification displays some promising value in this regard as well: HBsAg levels have been shown to 
correlate positively with cccDNA (an accurate marker of the burden of infected liver cells) in HBe-
positive CHB patients [21, 28] and has indeed displayed utility in predicting and monitoring response 
to therapy [10, 11, 29]. However, studies so far have found this correlation to be weaker in HBe-
negative HBV infected patients [21, 28, 30]. Further studies in HBe-negative populations could shed 
some light on HBsAg and cccDNA kinetics during later phases of HBV infection. 
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Natural history of HBV inactive carriers 
Among HBV-infected patients, the inactive carrier state generally has a very good prognosis; 
however, reactivation to active hepatitis, cirrhosis and hepatocellular carcinoma (HCC) are rare but 
nevertheless possible complications. 
Spontaneous reactivation 
Disease progression to HBe-negative active hepatitis with or without reversion to HBeAg positivity is 
a possible outcome for inactive carriers; this may happen spontaneously, or following 
immunosuppressant therapy or disease. 
Spontaneous relapse of hepatitis and reversion to HBe-positivity have been extensively studied in 
prospective studies of HBe-negative patients. A recent review by Villa et al. has highlighted that 
discordant relapse rates appear to stem from different study designs and populations. In studies of 
non-endemic populations, incidence of reactivation ranged from 0,03 to 0,8 per 100 person-years, 
whereas this incidence was somewhat higher in endemic areas (1,4 to 2,8 per 100 person-years). 
Relapse rate also seemed to vary according to sampling method: when patients were studied after 
recent seroconversion to HBe-negativity during follow-up, incidence of reactivation ranged from 0,8 
to 2,8 per 100 person-years, whereas those who were already HBe-negative at enrollment had 
inferior reactivation rates of 0,08 to 1,4 per 100 person-years. The authors conclude that longer time 
from seroconversion may account for this lower incidence of reactivation [22]. 
Accordingly, in asymptomatic HBe-negative Taiwanese patients, cumulative incidences of relapse 
were 10,2%, 17,4%, 19,3% and 20,2% at 5, 10, 15 and 20 years, respectively. The increases in 
cumulative incidence tended to be progressively lower as time went on, with approximately half of 
relapses occurring during the first 5 years of follow-up [31]. Both these data suggest that risk of 
spontaneous reactivation tends to decrease with time from seroconversion.  
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However, studying the rate of spontaneous relapse in true inactive carriers proves more difficult 
because only a few longitudinal studies correctly diagnose them with regular ALT and HBV DNA 
measurements during one year before beginning follow-up. 
Incidence rates from three prospective studies in which inactive carrier state was defined after at 
least 6 months of persistently normal ALT are summarized in table 1, as well as data from three 
additional studies on asymptomatic HBe-negative patients with normal ALT. 
The two factors most consistently associated with risk of relapse in HBe-negative patients are male 
gender [31-34] and older age at HBe seroconversion [31, 33, 34]. Other patient characteristics that 
seem to confer greater risk of reactivation are baseline ALT and HBV DNA levels [35], maximum ALT 
during follow-up, genotype C [34] and endemic geographic area [22]. It is possible that HBV primo-
infection at a very young age with a longer immune-tolerant phase accounts for the higher 
reactivation rate in endemic populations, where transmission occurs most commonly perinatally and 
in early childhood [2]. 
A study on true inactive carriers found no statistically significant difference in the age and sex 
between true inactive carriers who remained so and those who reactivated; however, the latter had 
significantly higher baseline serum ALT and HBV DNA [35]. 
Non-spontaneous reactivation 
Reactivation of active hepatitis in inactive HBV carriers (including HBsAg-negative anti-HBs-positive 
patients) has been observed during or after cytotoxic treatments for malignancies. It is most often 
asymptomatic, but a hepatitis flare with hepatic decompensation and even death can occur in 5% to 
40% of cases [36]. It appears to be more common when corticosteroids, anthracyclines or rituximab 
are part of the treatment regimen [36, 37]. Reactivation has also been described in association with 
imunossupressive drugs used in rheumatic and autoimmune diseases, including corticosteroids, 
methotrexate and anti-TNFα drugs [38]. 
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Major guidelines therefore preclude prophylactic tenofovir or entecavir for all HBsAg carriers during 
any cytotoxic or imunossupressive treatment and for 6 to 12 months thereafter [1, 5]. For HBV-
infected patients who have cleared HBsAg and have detectable serum HBV DNA (occult HBV 
infection), the EASL recommends similar prophylaxis; on the other hand, if HBV DNA is undetectable, 
either prophylaxis with lamivudine or no treatment with a strict follow-up with ALT and HBV DNA 
levels every 1 to 3 months are appropriate approaches. 
The natural history of inactive carriers is also influenced by human immunodeficiency virus (HIV) co-
infection. In general, untreated HIV infection is associated with higher HBV replication, higher 
reactivation rate and reduced liver necroinflammatory activity in comparison with HBV infection 
alone, probably due to CD4+ cell depletion and immune system impairment. Initiation of highly active 
antiretroviral therapy may help immune control of viral replication, but it is also associated with 
hepatitis reactivation due to the immune reconstitution syndrome [39]. Still, inactive carrier state 
alone does not preclude any changes in HIV infection treatment according to the European AIDS 
Clinical Society guidelines [40]. 
Spontaneous clearance 
The annual rate of HBsAg clearance among heterogeneous HBsAg carriers is 0,5% [5]. This is 
considered the best possible outcome of HBV infection; however, residual viral replication can persist 
and HBV DNA is detectable in the liver even decades later [41]. 
Incidences of HBsAg loss from three longitudinal studies in HBe-negative patients with baseline 
normal ALT are summarized in Table 2. Only one of them discriminated results from true inactive 
carriers classified after one year of PNALT and the almost two-fold higher HBsAg seroclearance rate 
in this population possibly reflects that [42]. 
Yuen et al. have extensively elucidated the natural history of disease after HBsAg clearance in a 
longitudinal study of 298 patients followed for a median of 3 years after HBsAg loss (96% of it 
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spontaneous). All became HBe-negative before clearing HBsAg and 52% of them developed anti-
HBsAg.  In a subset of 212 patients who had at least 4 ALT measurements, 82% maintained PNALT 
during the rest of follow-up; in those who didn’t (18%), alternative causes for transaminase elevation 
other than active HBV hepatitis were present in all but 6 (2,8%) of patients (fatty liver, hepatocellular 
carcinoma or intake of potentially hepatotoxic traditional herbal medicines). The number of patients 
with detectable serum HBV DNA diminished with time from HBsAg seroclearance; however, 
integrated HBV DNA remained detectable in all 29 liver biopsies performed and cccDNA in 23 of 
them. Five patients had clinical complications of cirrhosis (all with HBsAg clearance after 47 years of 
age; 3 had transient elastography readings compatible with cirrhosis within 1 year of seroclearance) 
and 7 patients developed HCC (all were men and lost HBsAg aged > 50 years; 6 had cirrhosis on 
ultrasound within 1 year of seroclearance) [41]. 
It seems HBsAg loss is associated with improved prognosis particularly when no cirrhosis has yet 
developed and with younger age at HBsAg  seroclearance. 
Complications and survival 
Studying the incidence of liver complications in inactive carriers is likewise hindered by the small 
number of prospective studies which correctly define this state. In two longitudinal studies of strictly 
defined inactive carriers followed for a median of 3,2 and 5,3 years, none developed cirrhosis or HCC 
(Table 3) [32, 43]. Another study on 145 true inactive carriers with a longer follow-up (mean of 8 
years) found two instances of HCC and no cases of liver-related death [44]. 
In a larger scale sample of 1932 Taiwanese inactive carriers, annual rates of cirrhosis and HCC were 
0,06% and 0,02%, respectively. Serum HBV DNA level was the most important predictor of both 
outcomes. Interestingly, its prognostic value for HCC was greater in HBe-negative patients with 
normal ALT and no cirrhosis when compared with the whole HBsAg-positive cohort; this greater 
association was not found for prediction of cirrhosis [45]. Another study on the same population 
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found older age and alcohol consumption to be predictors of HCC and liver-related death in inactive 
carriers; on the contrary, no statistical significant difference in outcomes was demonstrated for 
gender, smoking habits and high-normal versus low-normal ALT levels in inactive carriers [9]. 
Management of inactive carriers 
Due to its general excellent prognosis, antiviral treatment is not generally recommended for HBV 
patients in the inactive carrier state. 
Once true inactive carrier state is confirmed, regular lifelong monitoring with ALT levels every 6 to 12 
months and periodic HBV DNA measurements is advised [1]. Because liver biopsy is not routinely 
recommended in inactive carriers, hepatic fibrosis remains uninvestigated during the follow-up of 
most of these patients. To this end, transient elastography appears an advantageous fibrosis 
assessment tool that can easily be used for baseline and even serial monitoring of liver fibrotic 
changes. 
Decision to treat patients with ALT >2xULN and HBV DNA >20.000 IU/mL is unanimous [1, 5] but it is 
less firm when ALT is minimally elevated (<2xULN) and/or HBV DNA levels are between 20.000 and 
2000 IU/mL. Patients with normal ALT and HBV DNA levels between 2000 and 20.000 IU/mL (the 
aforementioned HBV DNA level “grey area”) should be followed more closely with ALT 
determinations every 3 months for at least three years, because as previously discussed, relapse to 
active hepatitis appears more likely during the beginning of follow-up [22, 31].  Indeed, in a study of 
217 HBe-negative asymptomatic patients with normal baseline ALT, time to reactivation (defined as 
ALT and HBV DNA elevation) after beginning of follow-up was analysed: the 10th percentile was 3,4 
months, which suggests that analytical assessment of inactive carriers every 3 months can detect 
approximately 90% of relapses [33]. When there are only small ALT or HBV DNA elevations (ALT 
<2xULN or HBV DNA <20.000 IU/mL), guidelines also suggest liver biopsy [5] or transient elastography 
[1] to assess severity of disease before decision to treat is made. 
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Though a rare complication, HCC is a possible life-threatening event; screening with liver ultrasound, 
with or without alpha-fetoprotein measurements, is recommended indefinitely [1, 5]. 
Discussion 
HBsAg inactive carriers represent the majority of hepatitis B virus carriers who have seroconverted to 
anti-HBe [5], making them an especially important subpopulation of chronic HBV patients, both due 
to their significant number but also because of the particularities in their management. Specifically, 
they are not candidates for any of the current hepatitis B therapies available. The clinician’s main 
goals when faced with an inactive carrier must be a) confirming inactive carrier status, b) monitoring 
for reactivation and c) screening for liver complications [5]. We will comment on each of these items 
separately. 
A. Confirming inactive carrier status 
Debate continues regarding the most recent update of lowering the HBV DNA cut-off level to 2000 
IU/mL for diagnosing inactive carriers. One study counter-argues this cut-off alteration with the 
evidence that 23% of inactive carriers diagnosed after one year of PNALT had at least one HBV DNA 
measurement between 2000 and 20.000 IU/mL during a median follow-up of 3 years [35]. The new 
cut-off level would therefore leave one-fifth of these probable inactive carriers robbed of this 
classification while still not fulfilling the criteria for chronic active hepatitis. However, we believe that 
this particular subset of patients has an important risk of active disease and according to guidelines 
warrants different management from true inactive carriers, deserving therefore clinical distinction. 
Guideline recommendations for these patients vary between tighter follow-up (with ALT 
determination every 3 months and HBV DNA measurements every 6 to 12 months for 3 years) and 
liver fibrosis assessment (with a non-invasive method such as transient elastography or even liver 
biopsy) [1, 5]. As such, a cut-off level of 2000 IU/mL seems to us more useful clinically: even though it 
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is more specific for inactive carriers, it is less likely to misdiagnose patients with active disease who 
might benefit from antiviral treatment. 
In recent years, HBsAg quantification has been gaining prominence as a tempting substitute for the 
year-long follow-up necessary to diagnose inactive carriers. As a standalone single-point test, an 
HBsAg level <1000 IU/mL demonstrated good discriminatory power for diagnosing inactive carrier 
state in a European population; diagnostic power was even stronger when associated with a same 
time-point HBV DNA level <2000 IU/mL [16]. Even though these cut-off levels remain to be tested and 
validated in different hepatitis B patient cohorts, quantitative HBsAg seems a very promising 
diagnostic marker. 
HBsAg levels are generally correlated with viremia, but in low replicative states such as inactive 
carrier state, they remain proportionally higher to those of serum HBV DNA [21, 28, 30], probably 
reflecting HBsAg secretion from integrated HBV DNA and/or reduced host immune control over 
HBsAg production versus viral replication. It provides additional information about the patient’s 
immune control over the disease and possibly about the extent of affected hepatocytes: HBsAg loss 
represents optimal viral suppression and lower HBsAg levels as well as higher rate of HBsAg decline 
during the course of the disease appear to be predictive of this outcome [16, 18]. 
As for the assessment of liver fibrosis in this subset of HBV-infected patients, it seems to us that 
despite being the gold-standard, liver biopsy does not constitute an optimal first-line exam in this 
population mainly because it is invasive, observer-dependent and carries a small risk of serious 
complications, making its use in asymptomatic patients with low risk of severe liver disease very 
questionable. 
When available, liver transient elastography represents a more convenient test, both for health-care 
providers and patients, in diagnosing inactive carriers and even serially monitoring their degree of 
fibrosis. Liver biopsy should be reserved for patients with unexplained ALT elevations of >2xULN, 
isolated viremia of >20.000 IU/mL or abnormal liver stiffness measurements. 
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B. Monitoring for reactivation 
There are few prospective studies of inactive carriers defined according to the most recent 
guidelines. Still, prognosis and outcomes are decidedly favorable in asymptomatic HBsAg carriers 
with PNALT levels and low viremia. 
Reactivation in true inactive carriers is a very rare outcome: incidences were 0,8 and 0,4 per 100 
person-years in two studies from France and Greece, respectively [32, 35]. Another Greek study 
revealed a surprising reactivation rate of 4,7 per 100 person-years [43]. Even though no significant 
differences in study design or population sampling method were reported, it is possible that in this 
study undisclosed alcohol consumption or unidentified advanced liver disease at baseline (no initial 
liver biopsies were performed) may account for this discrepant finding. 
Most longitudinal studies investigating reactivation in inactive carriers fail to mention HBeAg 
reversion rates; in the few who do so, these are almost negligible (0 to 0,07 per 100 person-years) 
[32, 33]. 
Monitoring for relapse of active hepatitis can be accomplished with regular ALT and HBV DNA 
measurements. As mentioned previously, HBV DNA elevations between 2000 and 20.000 IU/mL do 
not necessarily correspond to disease activity: these patients benefit from more frequent follow-up 
to clarify this. When faced with isolated viremia in this range and PNALT, liver fibrosis stage should be 
investigated with transient elastography, since active liver inflammation is an unlikely confounding 
factor in this situation. Conversely, isolated ALT elevations <2xULN may benefit more from liver 
biopsy and additional studies to exclude other causes of raised transaminase levels, such as for 
example  alcohol abuse, hepatic steatosis or HCC. 
C. Liver complications 
Cirrhosis and hepatocellular carcinoma are rare but possible outcomes even after years of inactive 
disease and even after HBsAg loss [9, 44]. Higher HBV DNA levels (within inactive carrier range), older 
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age and alcohol consumption were found to be risk factors for both complications in this 
subpopulation. It is interesting to note that HBV DNA has a proportionally greater predictor effect for 
HCC in inactive carriers compared to HBV chronic hepatitis in general, demonstrating the relevance of 
a viral-dependent, rather than fibrosis-dependent, oncogenic pathway in these patients [9, 45]. 
  
In conclusion, we consider hepatitis B inactive carrier state a relatively benign condition in the HBV 
infection spectrum, but only if accurately diagnosed. Transient elastograhy and the promising HBsAg 
quantification in serum are the two most recent major advances that have contributed to more 
accurate diagnosis of this state and simplified its follow up, obviating the need for biopsy in many 
circumstances. After correct diagnosis, lifelong monitoring is warranted for early detection of 
eventual reactivation and hepatic complications. The goal in clinical practice is to recognize all 
situations which mandate a change in management (be it with tighter follow-up, further 
investigations or treatment), so it can be implemented as soon as possible in order to minimize liver 
damage and negative clinical outcomes. 
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Tables 
Table 1 
Incidence of reactivation of hepatitis B in Hbe-negative patients. 
Author (date) Geographic area No. patients % of males Median follow-
up (years) 
No. Reactivationa 
(%) 
Reactivation 
incidence (per 
100 person-
years) 
No. Reversion 
Inactive carrier state diagnosed after a minimum of 6 months of follow-up 
Martinot-
Peignoux et al. 
(2002) [32] 
France 85b 54 3,2 1 (1) 0,8 0 
Papatheodoridis 
et al. (2008) [35] 
Greece 85 60 3 12 (14) 
 
4,7 n.a. 
Zacharakis et al. 
(2008) [43] 
Greece 195 n.a. 5,3 4 (2,1)c 
 
0,4 n.a. 
Asymptomatic HBe-negative population with baseline normal ALT 
Chu et al.d (2007) 
[31] 
Taiwan 1241 53 12,3 211 (17) 1,4 n.a. 
Kumar et al. 
(2009)e [33] 
India 217 74 6,3 43 (19,8) 3,1 1 
Tong et al. 
(2013) [44] 
USA 146f 47 8 20 (13,7) 
 
1,7 n.a. 
ALT, alanine aminotransferase; ULN, upper limit of normal. 
a Reactivation defined as ALT elevation >2xULN and/or serum HBV DNA ≥ 20.000 IU/L unless otherwise specified. 
b 2 patients had baseline serum HBV DNA >20.000 IU/L but were not excluded from follow-up 
c Definition of reactivation unknown. 
d Reactivation defined as ALT elevation >2xULN and detectable HBV DNA by hybridization assay (sensitivity = 140.000 copies/mL) 
e Reactivation defined as ALT elevation >2xULN and serum HBV DNA ≥ 20.000 IU/L or 100-fold rise in HBV DNA from previous levels. 
f 24 inactive carriers became so after antiviral treatment. 
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Table 2 
Incidence of HBsAg loss in HBe-negative HBsAg carriers with normal baseline ALT 
Author (date) Geographic area No. of patients % of males Mean follow-up 
(years) 
No. HBs clearance 
(%) 
Incidence rate (per 
100 person-years) 
Tong et al. (2013) 
[44] 
USA 146 47 8 13 (9) 1,1 
Martinot-Peignoux 
et al. (2013) [42] 
France 54 n.a. 10 8 (15) 1,9 
Chu et al. (2007) 
[46] 
Taiwan 1965 55 10,8 245 (12) 1,2  
 HBsAg, hepatitis B s antigen; ALT, alanine aminotransferase 
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Table 3 
Liver-related outcomes in inactive carriersa (incidence per 100 person-years) 
Author (date) Geographic area No. patients % of males Follow-up (years) HCC incidence Liver-related 
mortality incidence 
Tong et al. (2013) 
[44] 
USA 146b 47 8 0,17 0 
Chen et al. (2010) 
[9] 
Taiwan 1932 58 13,1 0,06 0,02 
Zacharakis et al. 
(2008) [43] 
Greece 195 n.a. 5,3 0 0d 
Martinot-Peignoux 
et al. (2002) [32] 
France 85c 54 3,2 0d 0d 
HBsAg, hepatitis B s antigen; ALT, alanine aminotransferase; HCC, hepatocellular carcinoma 
a Inactive carriers defined as HBe-negative HBsAg carriers with normal baseline ALT and HBV DNA <2000 IU/mL unless otherwise specified. 
b 24 patients became inactive carriers after antiviral treatment 
c 16 patients had HBV DNA >2000 IU/mL; 2 >20.000 IU/mL 
d Though not explicit in the text, assumed to be zero. 
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